Bayesian Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-66,900
| Closed | -$452K | – | 919 |
|
|
2024
Q4 | $452K | Buy |
+66,900
| New | +$452K | 0.06% | 391 |
|
|
2024
Q3 | – | Sell |
-42,400
| Closed | -$318K | – | 995 |
|
|
2024
Q2 | $318K | Buy |
+42,400
| New | +$318K | 0.04% | 491 |
|
|
2023
Q4 | – | Sell |
-59,611
| Closed | -$456K | – | 995 |
|
|
2023
Q3 | $456K | Buy |
+59,611
| New | +$456K | 0.05% | 392 |
|
|
2023
Q2 | – | Sell |
-24,095
| Closed | -$161K | – | 1029 |
|
|
2023
Q1 | $161K | Sell |
24,095
-37,300
| -61% | -$249K | 0.02% | 637 |
|
|
2022
Q4 | $473K | Buy |
+61,395
| New | +$473K | 0.07% | 372 |
|
|
2022
Q2 | – | Sell |
-25,700
| Closed | -$184K | – | 1039 |
|
|
2022
Q1 | $184K | Buy |
+25,700
| New | +$184K | 0.03% | 663 |
|